Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary.
about
Management of HIV Infection during Pregnancy in the United States: Updated Evidence-Based Recommendations and Future Potential PracticesA risk-factor guided approach to reducing lactic acidosis and hyperlactatemia in patients on antiretroviral therapyInfluence of adverse drug reactions on treatment success: prospective cohort analysis of HIV-infected individuals initiating first-line antiretroviral therapy in IndiaReasons and Risk Factors for the Initial Regimen Modification in Chinese Treatment-Naïve Patients with HIV Infection: A Retrospective Cohort AnalysisMagnitude of Antiretroviral Drug Toxicity in Adult HIV Patients in Ethiopia: A cohort study at seven teaching hospitals.LIPODYSTROPHY SYNDROME IN HIV-INFECTED CHILDREN ON HAART.Evaluating Liver Fibrosis by Transient Elastometry in Patients With HIV-HCV Coinfection and Monoinfection.Quality of life in individuals living with HIV/AIDS attending a public sector antiretroviral service in Cape Town, South Africa.Diagnosing latent tuberculosis in high-risk individuals: rising to the challenge in high-burden areas.Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South AfricaHuman immunodeficiency virus infection and the liverHIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 countries.Practical Management of HIV-Associated Anemia in Resource-Limited Settings: Prospective Observational Evaluation of a New Mozambican GuidelineLiver Enzymes Abnormalities among Highly Active Antiretroviral Therapy Experienced and HAART Naïve HIV-1 Infected Patients at Debre Tabor Hospital, North West Ethiopia: A Comparative Cross-Sectional Study.Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathyIncreases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South AfricaReduction in early mortality on antiretroviral therapy for adults in rural South Africa since change in CD4+ cell count eligibility criteria.Hyperlactatemia in a group of HIV patients living in Yaounde-Cameroon.The effects of setarud on the immunological status of HIV-positive patients: Efficacy of a novel multi-herbal drug.Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana.Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir.Chronic myeloid leukaemia and human immunodeficiency virus (HIV) infection.Reasons and predictors for antiretroviral therapy change among HIV-infected adults at South West Ethiopia.
P2860
Q26738453-8250936F-E0BA-42AC-B025-BD77B86CEC2CQ28477707-D59C99D2-6E14-41DA-A734-652E760E7BD3Q28540682-C2E4777B-E534-4454-9EE0-CE16E2C6616BQ28546795-40F78DA9-BB9A-413E-A74E-00D3B9E1AF39Q33596144-25344B30-C296-4C46-A9F1-3371EA38BDE1Q34058478-FA687220-CB49-428B-B45B-02CAB608418FQ34349036-7CDDA2F6-E76C-4909-BB9A-FB00FA58F2BCQ34486279-D416D218-02CB-4128-9E9A-C669E5A78115Q35336540-D2116B2B-0787-43EC-B472-175091B3809DQ35856520-0973D183-0553-4E5E-B447-DE80B3D383E4Q35875848-50CC6A99-75C5-4076-8968-A7F7D184C96AQ35917583-FD8E04AD-FAFE-4690-990B-EC5FAA4E167DQ36406927-47124C4B-2498-4B75-AF02-4987C0ACBB0AQ37132172-07EDA612-C950-4F82-B493-AB7794BED1B4Q37251569-90AFFB6F-B2D7-44DB-9FDC-C4C6DC378936Q37330398-E45AA353-187F-42AD-8CC6-70BEF6B4473AQ37401923-1BA1CE13-0B65-4427-820E-DE201123D081Q37506855-5D9A8FAB-5918-4F9B-B3B5-C029A5CAB207Q40117873-5BF3F5BA-B597-47FB-A6B7-924AC0FDFDB1Q40797865-2369628F-0945-4EEA-A656-11A5E4EDB021Q42234057-E8F73934-92A8-4B8D-B6CD-B8E08A366679Q45358123-DA1B24F1-7823-404D-9E15-0B28BC03BFA3Q55257500-E2CBFF24-E0EE-4F32-839E-2E3D24A917FF
P2860
Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antiretroviral therapy-associa ...... llenge of a limited formulary.
@en
Antiretroviral therapy-associa ...... llenge of a limited formulary.
@nl
type
label
Antiretroviral therapy-associa ...... llenge of a limited formulary.
@en
Antiretroviral therapy-associa ...... llenge of a limited formulary.
@nl
prefLabel
Antiretroviral therapy-associa ...... llenge of a limited formulary.
@en
Antiretroviral therapy-associa ...... llenge of a limited formulary.
@nl
P2093
P356
P1476
Antiretroviral therapy-associa ...... llenge of a limited formulary.
@en
P2093
Daniel R Kuritzkes
Francois Venter
Henry Sunpath
Rajesh T Gandhi
Richard A Murphy
P304
P356
10.1086/521112
P407
P478
196 Suppl 3
P577
2007-12-01T00:00:00Z